News stories about Lannett Co (NYSE:LCI) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lannett Co earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.5935964641483 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

A number of analysts recently commented on the company. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Lannett Co in a research report on Thursday, June 8th. BidaskClub cut Lannett Co from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research cut Lannett Co from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Deutsche Bank AG restated a “hold” rating and issued a $23.00 price target (up previously from $22.00) on shares of Lannett Co in a research report on Monday, July 17th. Finally, Robert W. Baird restated an “outperform” rating and issued a $18.00 price target on shares of Lannett Co in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. Lannett Co presently has an average rating of “Hold” and a consensus price target of $27.50.

Lannett Co (NYSE LCI) traded up 1.55% during mid-day trading on Friday, hitting $16.40. The company had a trading volume of 769,048 shares. The firm’s market capitalization is $610.57 million. Lannett Co has a 12 month low of $15.75 and a 12 month high of $39.99. The company has a 50-day moving average price of $20.02 and a 200 day moving average price of $21.30.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at

Lannett Co Company Profile

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Insider Buying and Selling by Quarter for Lannett Co (NYSE:LCI)

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with's FREE daily email newsletter.